Drugs / IFN alfa-2b XL
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01010646 | Mar 2010 → Sep 2012 | chronic hepatitis C virus infection | ANRS, Emerging Infectious Diseases | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IFN alfa-2b XL | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01010646 ↗ |
| Known as | Interferon alfa-2b XL | “Interferon alfa-2b XL (IFN alfa-2b XL) is a novel sustained release interferon α-2b drug product that is being developed by FLAMEL TECHNOLOGIES using its Medusa® technology,...” NCT01010646 ↗ |
| Route | Subcutaneous | “IFN alfa-2b XL 27 MUI administered once a week for 12 weeks by subcutaneous injections” NCT01010646 ↗ |